GlassScriptPhysician profile
Matthew Adams
NPI 1124361076
$30,683.56
in general payments reported to CMS, 2019-2025
24 companies · $4,560 in 2025
The $4,560 reported for 2025 was more than what 87% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $4,074 · 2021: $1,198 · 2022: $1,138 · 2023: $4,156 · 2024: $15K · 2025: $4,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $12K · Food and Beverage: $5,040 · Consulting Fee: $2,800 · Travel and Lodging: $2,140 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,850 · Entertainment: $117 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $11,840.00 |
| Food and Beverage | $5,040.32 |
| Consulting Fee | $2,800.00 |
| Travel and Lodging | $2,139.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,850.00 |
| Entertainment | $117.45 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $14,780.23 | 2020-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $4,883.92 | 2020-2025 | Vabysmo, Susvimo, Lucentis |
| Harrow Eye, LLC | $3,122.44 | 2025 | Iheezo, Triesence |
| Eyepoint US, INC. | $2,427.74 | 2019-2023 | |
| Carl Zeiss Meditec USA, INC. | $1,214.26 | 2024 | |
| Ani Pharmaceuticals, INC. | $573.71 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Allergan, INC. | $572.13 | 2019-2021 | |
| Alcon Vision LLC | $537.12 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $456.20 | 2019-2024 | Eylea, Eylea Hd |
| Astellas Pharma US INC | $336.73 | 2023-2025 | Izervay |
| Biotissue Holdings INC. | $327.57 | 2025 | |
| Dutch Ophthalmic, USA | $292.01 | 2020-2021 | |
| Abbvie INC. | $252.93 | 2022-2025 | Ozurdex |
| Apellis Pharmaceuticals, INC. | $200.24 | 2024-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $147.68 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $137.96 | 2021 | |
| Bausch & Lomb Americas INC. | $120.00 | 2022 | |
| Optos, INC. | $117.45 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.19 | 2020-2021 | |
| Akorn, INC. | $22.62 | 2019 | |
| Lkc Technologies, INC. | $21.23 | 2025 | |
| Rxsight INC | $18.31 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Oyster Point Pharma, INC. | $16.82 | 2024 | Ryzumvi, Tyrvaya |
| Mallinckrodt Hospital Products INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.